Search Results for: ME/CFS

October 9, 2026

Exploratory clinical and immunological changes following Tixagevimab/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME/CFS and persistent circulating spike protein.

Publication date: Oct 07, 2026 Persistent circulating SARS-CoV-2 spike protein has been proposed as a potential contributor to long-COVID pathophysiology. Whether administration of spike-targeting monoclonal antibodies is followed by changes ... Read more

September 10, 2026September 10, 2026

Common Genomic Networks Found Across Long COVID, ME/CFS, and PTSD

Coronavirus News

Publication date: Sep 09, 2026 According to the report, researchers investigated the impact of a novel compound, designated “Compound X,” on neuronal activity in vitro. The study demonstrated a significant ... Read more

September 6, 2026

Beyond genes: EpiSwitch® and Orion platform-powered 3D genome architecture biomarkers reveal shared biology across ME/CFS, long COVID, PTSD, rheumatoid arthritis, and multiple sclerosis.

Coronavirus Literature

Publication date: Aug 22, 2026 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID (LC19), post-traumatic stress disorder (PTSD), rheumatoid arthritis (RA), and multiple sclerosis (MS) are clinically distinct disorders that share ... Read more

August 29, 2026August 29, 2026

Skeletal muscle properties in long COVID and ME/CFS differ from those induced by bed rest.

Coronavirus Literature

Publication date: Jul 28, 2026 Patients with long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suffer from post-exertional malaise. The accompanying physical inactivity may contribute to a lower aerobic capacity ... Read more

August 23, 2026

A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.

Coronavirus Literature

Publication date: Aug 20, 2026 Post-exertional malaise (PEM), the defining feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is increasingly recognized in individuals with Long COVID. Although traditionally viewed as symptom ... Read more

August 2, 2026

Circulating extracellular vesicles-microRNAs as potential biomarkers for the identification of ME/CFS: differentiating fatigue-related conditions.

Coronavirus Literature

Publication date: Jul 27, 2026 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating, multi-systemic condition that has gained renewed global attention due to its clinical overlap with the growing population ... Read more

August 1, 2026

Therapeutic plasma exchange and immunomodulatory strategies in post-infectious syndromes: A review of immune dysregulation in PTLDS, long COVID, ME/CFS, and PANS/PANDAS.

Coronavirus Literature

Publication date: Aug 01, 2026 Post-infectious syndromes including post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and pediatric acute-onset neuropsychiatric syndrome (PANS)/pediatric autoimmune neuropsychiatric disorders associated ... Read more

July 29, 2026

Pacing and energy management with digital tools for conditions with chronic fatigue: What we know so far in ME/CFS and Long COVID.

Coronavirus Literature

Publication date: Jul 01, 2026 Open Access PDF Concepts Keywords Covid Cfs Digital Chronic Fatigue Conditions Management Covid Pacing Digit Digital Energy Fatigue Long Management Pacing Semantics Type Source Name ... Read more

July 26, 2026

Prospective, Randomized, Double-blind, Placebo-controlled Phase 2b Trial Evaluating the Efficacy and Safety of the Anti-CD19 Monoclonal Antibody Inebilizumab Compared With Placebo in Patients With Post-acute Infection Syndromes Fulfilling ME/CFS Criteria (PIONEER)

Coronavirus News

Publication date: Jul 21, 2026 Post-acute infection syndromes (PAIS) are long-lasting health problems that can develop after an infection. They include post-COVID-19 syndrome and similar illnesses following other infections. Some ... Read more

July 26, 2026

Prospective, Randomized, Double-blind, Placebo-controlled Phase 2b Trial Evaluating the Efficacy and Safety of the Anti-CD19 Monoclonal Antibody Inebilizumab Compared With Placebo in Patients With Post-acute Infection Syndromes Fulfilling ME/CFS Criteria (PIONEER)

Coronavirus News